Equity
€315,147 ▲ 10.4%
LIDEFARMA has made a profit in every financial year since 2009.
LIDEFARMA
Lifetime
17 annual accounts with figures on one time axispeak €146,809 (2025)
€146,809▲ 66.0%
peak €62,177 (2025)
€62,177▲ 140%
peak €315,147 (2025)
€315,147▲ 10.4%
€179,880▲ 77.4%
peak 0.5 FTE (2018)
-not published
Board4 names since 2008
2 directors and 1 other
Documentsfilings and deeds
25-08-202625 days late
2025micro format
Gross margin from €88,416 to €146,809Result from €25,890 to €62,177Dividend €32,527Debts from €101,421 to €179,880Investments €69,021
Key points
from the 2025 annual accountsTurnover
≈ €520,000 estimated
The micro format states no turnover.
Debts
€179,880 ▲ 77.4%
Debts rose by €78,459 in 2025.
Investments
€69,021 2.9 × depreciation
Green is investment, beige is depreciation.
Filings
17 annual accounts since 2009
Six of the last ten came late. The 2022 accounts came latest: 30 days after the end of the period.
Position in the sector
€62,177
Higher net result than 91% of companies in retail trade. Sector median €4,763 · 25,252 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 34,721 companies had the same profile as LIDEFARMA has now. Each dot stands for 87 companies, two years later.
95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,721 companies, not a prediction for LIDEFARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
2 directors resigning, 2 reappointments
Resignations: (director) and (director) · Reappointments: (director) and (director) · Director discharge: · General meeting of 11-12-2023 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0899688064
Incorporation
published on 19-08-2008 · Gazette deed
First establishment
Kerkstraat 32, Lierde
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| LIDEFARMA Lierde | €495,027 | €146,809 | 63.7% | - |
| APOTHEEK DAEMERS Ghent | €543,731 | €155,899 | 41.4% | - |
| APOTHEEK VAN WAMBEKE Oudenaarde | €498,356 | €131,531 | 44.5% | 1.1 |
| Apotheek Het Gasthuis Aarschot | €508,948 | €144,460 | 91.2% | - |
| Pharmacie PIROTTE à BOURCY Bastogne | €485,322 | €155,253 | 89.7% | - |
| AXCOFARMA Diepenbeek | €489,172 | €141,281 | 9.7% | - |
| APOTHEEK HEIRBAUT Asse | €472,369 | €138,134 | 60.8% | - |
These companies have the same main activity as LIDEFARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €472,000 and €544,000, founded between 2007 and 2008.
Official details
Source: KBO- Status
- Active since 07-08-2008Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 3 others
- Establishment unit
- 2.173.076.4499570 Lierde, since 07-08-2008
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Insights on LIDEFARMA
LIDEFARMA files the micro format. That format states no turnover. The gross margin rose from €65,484 in 2009 to €146,809 in 2025.
The balance sheet grew most in 2010 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about LIDEFARMA
- What is the company number of LIDEFARMA?
- The company number of LIDEFARMA is 0899.688.064. The VAT number is the same number with BE in front: BE 0899.688.064.
- Where is LIDEFARMA based?
- The registered office is at Kerkstraat 24A, 9570 Lierde.Company details
- What does LIDEFARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of LIDEFARMA?
- LIDEFARMA is a private limited company (BV).
- When was LIDEFARMA founded?
- LIDEFARMA was founded on 07-08-2008.
- Is LIDEFARMA still active?
- Yes, LIDEFARMA is an active enterprise in the KBO register.
- How many employees does LIDEFARMA have?
- LIDEFARMA had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of LIDEFARMA?
- The turnover in financial year 2025 is ≈ €520,000. This figure is estimated from the gross margin of €146,809 and 39 comparable companies (NACE 477). It probably lies between €390,000 and €950,000.
- Is LIDEFARMA profitable?
- In financial year 2025, LIDEFARMA made a profit of €62,177.
- Where can I find the annual accounts of LIDEFARMA?
- LIDEFARMA filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of LIDEFARMA due?
- LIDEFARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.